In addition to trametinib, binimetinib, and cobimetinib which have demonstrated enhanced anti-tumor activity and improved response rates in combination with their respective BRAF inhibitors in patients with metastatic BRAF V600E-mutant NSCLC, MEK inhibitors are currently being explored in combination strategies with other targeted or immunotherapeutic agents in NSCLC. This evidence concerns the gene MAP2K7 and neoplasm.